Keyword: Alimta

Altogether, seven foreign pharmas won bids in the expanded government drug purchase scheme versus only two in the original "4+7" pilot.

Key oncology wins helped drive Pfizer and Merck to the top of the Dow in 2018, but the pharma sector faces plenty of hurdles this year.

Investors worried last year that Merck couldn’t replicate its Keytruda-chemo combo success in a phase 3 trial. But it just did.

Eli Lilly has already foiled wannabe generic Alimta makers in court—and now it’s prevailed over one company taking the inter partes review route, too.

Mylan called Allergan's Restasis licensing agreement "desperate" and a "transparent" delay tactic in a federal court filing.

The U.K. Supreme Court has handed Eli Lilly a huge patent victory for its cancer drug Alimta in a battle with Actavis, protecting some European sales.

Your move, Bristol-Myers Squibb and AstraZeneca. Merck’s Keytruda-chemo combo has its first-line lung cancer approval.

An appeals court ruled against generics challenger Teva, potentially protecting Eli Lilly's cancer med Alimta until 2022.

The University of Minnesota wants a piece of Gilead’s hep C business. The school sued for patent infringement Monday, seeking royalties on the drugs’ multibillion-dollar sales.